0.00
price down icon100.00%   -17.03
after-market アフターアワーズ: 17.04 17.04 +
loading
前日終値:
$17.03
開ける:
$0
24時間の取引高:
0
Relative Volume:
0.00
時価総額:
$884.18M
収益:
$109.78M
当期純損益:
$114.54M
株価収益率:
0.00
EPS:
2.2046
ネットキャッシュフロー:
$268.74M
1週間 パフォーマンス:
-100.00%
1か月 パフォーマンス:
-100.00%
6か月 パフォーマンス:
-100.00%
1年 パフォーマンス:
-100.00%
1日の値動き範囲:
Value
$0.00
$0.00
1週間の範囲:
Value
$0.00
$17.08
52週間の値動き範囲:
Value
$0.00
$21.03

Theravance Biopharma Inc Stock (TBPH) Company Profile

Name
名前
Theravance Biopharma Inc
Name
セクター
Healthcare (1067)
Name
電話
650-808-6000
Name
住所
UGLAND HOUSE, SOUTH CHURCH STREET, GEORGE TOWN, GRAND CAYMAN
Name
職員
90
Name
Twitter
Name
次回の収益日
2026-11-09
Name
最新のSEC提出書
Name
TBPH's Discussions on Twitter

Compare TBPH vs VRTX, REGN, MRNA, ARGX, RVMD

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
TBPH icon
TBPH
Theravance Biopharma Inc
0.00 884.18M 109.78M 114.54M 268.74M 2.2046
VRTX icon
VRTX
Vertex Pharmaceuticals Inc
526.19 133.37B 12.34B 4.34B 3.71B 16.87
REGN icon
REGN
Regeneron Pharmaceuticals Inc
788.04 81.13B 14.92B 4.42B 3.79B 41.04
MRNA icon
MRNA
Moderna Inc
198.88 79.40B 2.23B -3.19B -1.60B -8.1462
ARGX icon
ARGX
Argen X Se Adr
959.49 60.03B 4.16B 1.29B 734.26M 19.58
RVMD icon
RVMD
Revolution Medicines Inc
204.97 43.93B 742.00K -1.37B -1.07B -7.0731

Theravance Biopharma Inc Stock (TBPH) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2026-03-05 ダウングレード Oppenheimer Outperform → Perform
2026-03-04 ダウングレード B. Riley Securities Buy → Neutral
2025-12-03 開始されました Oppenheimer Outperform
2025-09-12 開始されました B. Riley Securities Buy
2024-08-06 ダウングレード Leerink Partners Outperform → Market Perform
2024-04-12 開始されました BTIG Research Buy
2024-01-08 ダウングレード Evercore ISI Outperform → In-line
2022-05-23 開始されました SVB Leerink Outperform
2021-11-05 アップグレード JP Morgan Underweight → Neutral
2021-09-15 ダウングレード JP Morgan Overweight → Underweight
2021-08-25 ダウングレード Morgan Stanley Overweight → Underweight
2021-08-24 ダウングレード Cowen Outperform → Market Perform
2020-10-14 アップグレード Morgan Stanley Equal-Weight → Overweight
2020-07-07 開始されました JP Morgan Overweight
2020-06-15 開始されました Morgan Stanley Equal-Weight
2020-05-13 開始されました Cowen Outperform
2020-01-08 繰り返されました H.C. Wainwright Buy
2019-11-06 アップグレード Robert W. Baird Underperform → Neutral
2019-10-29 開始されました H.C. Wainwright Buy
2018-03-29 再開されました Piper Jaffray Overweight
2017-08-17 開始されました Evercore ISI Outperform
2017-06-16 開始されました Cantor Fitzgerald Overweight
2017-05-11 繰り返されました Needham Buy
2016-12-21 開始されました Needham Buy
2016-11-03 開始されました Piper Jaffray Overweight
2016-10-12 ダウングレード Robert W. Baird Neutral → Underperform
2016-08-03 ダウングレード BofA/Merrill Neutral → Underperform
2016-06-20 開始されました Guggenheim Buy
2016-06-20 繰り返されました Leerink Partners Outperform
2016-05-12 開始されました Leerink Partners Outperform
2016-05-05 ダウングレード BofA/Merrill Buy → Neutral
2015-02-03 アップグレード Robert W. Baird Underperform → Neutral
すべてを表示

Theravance Biopharma Inc (TBPH) 最新ニュース

pulisher
Sep 25, 2026

Theravance Biopharma (TBPH) shares were canceled on September 23 after its Zymeworks merger. - Stock Titan

Sep 25, 2026
pulisher
Sep 25, 2026

Theravance Biopharma Insider Brett Grimaud Reports Complete Share Cancellation Following Zymeworks Merger - Kalkine Media

Sep 25, 2026
pulisher
Sep 24, 2026

Form 4 Theravance Biopharma For: 24 September By Investing.com - Investing.com Canada

Sep 24, 2026
pulisher
Sep 24, 2026

Zymeworks now owns Theravance Biopharma (TBPH). A director's shares were canceled for cash and milestone rights. - Stock Titan

Sep 24, 2026
pulisher
Sep 24, 2026

A director's shares became rights to $17 each plus a contingent payment in Theravance Biopharma's (TBPH) merger. - Stock Titan

Sep 24, 2026
pulisher
Sep 24, 2026

A 150,000-share insider option was cancelled without payment in Theravance Biopharma (TBPH)'s merger. - Stock Titan

Sep 24, 2026
pulisher
Sep 24, 2026

Vancouver biotech Zymeworks closes US$929M Theravance deal - biv.com

Sep 24, 2026
pulisher
Sep 24, 2026

Zymeworks Completes Acquisition of Theravance Biopharma - Indovizka.com

Sep 24, 2026
pulisher
Sep 24, 2026

TBPH Suspended by BTIGAnalyst Rating Remains Neutral - GuruFocus

Sep 24, 2026
pulisher
Sep 23, 2026

Zymeworks Finalizes Merger with Theravance Biopharma and Launches $350M Senior Secured Notes - Kalkine Media

Sep 23, 2026
pulisher
Sep 23, 2026

Precision Trading with Theravance Biopharma Inc. (TBPH) Risk Zones - Stock Traders Daily

Sep 23, 2026
pulisher
Sep 23, 2026

Zymeworks completes acquisition of Theravance Biopharma By Investing.com - Investing.com Australia

Sep 23, 2026
pulisher
Sep 23, 2026

Theravance Biopharma CEO Rick E Winningham resigns; Kristin Stafford, Scott Platshon and Paul Schneider named directors - TradingView

Sep 23, 2026
pulisher
Sep 23, 2026

Theravance Biopharma (Nasdaq: TBPH) is named in a notice to remove its shares from Nasdaq. - Stock Titan

Sep 23, 2026
pulisher
Sep 23, 2026

Zymeworks completes acquisition of Theravance Biopharma - Investing.com

Sep 23, 2026
pulisher
Sep 23, 2026

Theravance Biopharma, Inc. Announces Resignation of Rick E Winningham from Chief Executive Officer, Effective September 23, 2026 - marketscreener.com

Sep 23, 2026
pulisher
Sep 23, 2026

A $350 million debt issue helped fund Zymeworks (ZYME)'s Theravance acquisition, with cash due per eligible share. - Stock Titan

Sep 23, 2026
pulisher
Sep 22, 2026

Theravance Biopharma, Inc.(NasdaqGM:TBPH) dropped from S&P Pharmaceuticals Select Industry Index - marketscreener.com

Sep 22, 2026
pulisher
Sep 22, 2026

Theravance Biopharma, Inc.(NasdaqGM:TBPH) dropped from NASDAQ Biotechnology Index - marketscreener.com

Sep 22, 2026
pulisher
Sep 18, 2026

Theravance Biopharma issues disclosures amid Zymeworks merger - TipRanks

Sep 18, 2026
pulisher
Sep 18, 2026

Form 8K Theravance Biopharma Inc For: 18 September By Investing.com - Investing.com Nigeria

Sep 18, 2026
pulisher
Sep 18, 2026

Theravance Biopharma Shareholders Endorse Merger with Zymeworks Inc. - Kalkine Media

Sep 18, 2026
pulisher
Sep 18, 2026

Theravance Biopharma shareholders approve merger with Zymeworks - Investing.com

Sep 18, 2026
pulisher
Sep 18, 2026

Theravance Biopharma shareholders approve merger with Zymeworks By Investing.com - Investing.com Nigeria

Sep 18, 2026
pulisher
Sep 18, 2026

Theravance Biopharma SVP Farnum Rhonda Sells 13,314 Shares at $17.03 Each - Kalkine Media

Sep 18, 2026
pulisher
Sep 18, 2026

Theravance Biopharma, Inc. (TBPH) Stock Analysis: Navigating the Biotech Seas with Strategic Collaborations - DirectorsTalk Interviews

Sep 18, 2026
pulisher
Sep 17, 2026

Theravance Biopharma (TBPH) Insider Sale: SVP, COMM & MEDICAL AF - GuruFocus

Sep 17, 2026
pulisher
Sep 17, 2026

Theravance Biopharma SVP Rhonda Farnum sells $226k in stock - Investing.com India

Sep 17, 2026
pulisher
Sep 17, 2026

Theravance Biopharma SVP Rhonda Farnum sells $226k in stock By Investing.com - Investing.com South Africa

Sep 17, 2026
pulisher
Sep 17, 2026

Pre-arranged stock sale at Theravance Biopharma (TBPH) - Stock Titan

Sep 17, 2026
pulisher
Sep 15, 2026

Theravance Biopharma (NASDAQ: TBPH) officer plans $226,793 stock sale - Stock Titan

Sep 15, 2026
pulisher
Sep 13, 2026

Price-Driven Insight from (TBPH) for Rule-Based Strategy - Stock Traders Daily

Sep 13, 2026
pulisher
Sep 11, 2026

Theravance Biopharma Inc (NASDAQ: TBPH) Share Price, TBPH Stock News, TBPH Share Price & Updates - kalkine.com.au

Sep 11, 2026
pulisher
Sep 10, 2026

Form 8K Theravance Biopharma Inc For: 10 September By Investing.com - Investing.com South Africa

Sep 10, 2026
pulisher
Sep 10, 2026

Theravance Bi in merger with Zymeworks faces shareholder suits, supplements proxy with disclosures - TradingView

Sep 10, 2026
pulisher
Sep 09, 2026

Theravance Bio (TBPH) Up 0.8% Since Last Earnings Report: Can It Continue? - Yahoo Finance

Sep 09, 2026
pulisher
Sep 04, 2026

Theravance Biopharma Inc. (TBPH) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research

Sep 04, 2026
pulisher
Sep 04, 2026

Theravance Biopharma Inc. (TBPH) Financials – Balance Sheet, Profit & Loss, Cash Flow - Value Research

Sep 04, 2026
pulisher
Sep 02, 2026

How (TBPH) Movements Inform Risk Allocation Models - Stock Traders Daily

Sep 02, 2026
pulisher
Aug 25, 2026

Theravance Biopharma reports CYPRESS Phase 3 miss but FDA grants Type C meeting to discuss future trial - TradingView

Aug 25, 2026
pulisher
Aug 25, 2026

Theravance Biopharma (NASDAQ:TBPH): What Could Its Scheduled Update Reveal? - Kalkine Media

Aug 25, 2026
pulisher
Aug 25, 2026

FDA says Theravance (TBPH) needs more data on nOH drug trial - Stock Titan

Aug 25, 2026
pulisher
Aug 24, 2026

Theravance (TBPH) Q1 2026 Scorecard: EPS Beats Its Estimate in the Current Update; Closing Move: The Stock Records a Flat ReactionForward EPS Estimate - vinanet.vn

Aug 24, 2026
pulisher
Aug 21, 2026

Theravance (NASDAQ: TBPH) sets vote on cash buyout with ampreloxetine CVR upside - Stock Titan

Aug 21, 2026
pulisher
Aug 20, 2026

Madison Avenue Partners, LP Trims Theravance Biopharma Inc (TBPH) Stake in Portfolio Rebalancing Move - GuruFocus

Aug 20, 2026
pulisher
Aug 19, 2026

Theravance Biopharma, Inc. Revenue Breakdown – NASDAQ:TBPH - TradingView

Aug 19, 2026
pulisher
Aug 19, 2026

Theravance (TBPH) Update: Rises 0.18% to $16.98 on the Day; Price Setup: Traders Can Monitor the $16.13-$17.83 RangeSupport Level Bounce - vinanet.vn

Aug 19, 2026
pulisher
Aug 17, 2026

Theravance Biopharma (TBPH) Edges Higher to $16.97, Trapped Between Key Support and ResistanceFactor Valuation - vinanet.vn

Aug 17, 2026

Theravance Biopharma Inc (TBPH) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
$117.83
price down icon 3.06%
$35.80
price down icon 0.91%
$58.21
price down icon 0.14%
$255.96
price up icon 2.55%
ONC ONC
$360.85
price up icon 0.24%
$204.97
price up icon 2.56%
大文字化:     |  ボリューム (24 時間):